Shattuck Labs, Inc. (STTK) announced on Monday that the FDA has granted orphan drug designation to their leading clinical candidate, SL-172154, for the treatment of Acute Myeloid Leukemia (AML).
The company also anticipates presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with azacitidine. This trial focuses on frontline treatment for higher-risk myelodysplastic syndromes and TP53m AML patients and will be showcased at the European Hematology Association 2024 Congress via a poster presentation.
Acute Myeloid Leukemia is a type of cancer that impacts the blood and bone marrow, characterized by an excessive proliferation of immature white blood cells.
